Fulminant hepatitis as an immune‐related adverse event after nivolumab treatment
Gespeichert in:
| Veröffentlicht in: | Pathology international 2019-07, Vol.69 (7), p.434-436 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 436 |
|---|---|
| container_issue | 7 |
| container_start_page | 434 |
| container_title | Pathology international |
| container_volume | 69 |
| creator | Inamori, Osamu Miyagawa‐Hayashino, Aya Ueno, Akihisa Hongo, Fumiya Sonobe, Yuta Hojo, Tomohito Konishi, Eiichi |
| description | |
| doi_str_mv | 10.1111/pin.12812 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2275011431</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2275011431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3442-1960068b8e258b892b1424d5675c0a3cc1a78ffcb34a5294a8efe5dec33d5db33</originalsourceid><addsrcrecordid>eNp1kMtKAzEUhoMotlYXvoAMuHIxba5zWUpptVBURNchM3MGU-Zmkql05yP4jD6J0anuDIecA-fjO_AjdE7wlPg363QzJTQh9ACNCec4JAmND_3MKA4Fj9gInVi7wZjELMLHaMQ8HYmUjNHjsq9q3ajGBS_QKaedtoHy1QS6rvsGPt8_DFTKQRGoYgvGQgBb8LgqHZig0du26muVBc6AcrXfnKKjUlUWzvZ9gp6Xi6f5bbi-v1nNr9dhzjinIUkjjKMkS4AK_6c0I5zyQkSxyLFieU5UnJRlnjGuBE25SqAEUUDOWCGKjLEJuhy8nWlfe7BObtreNP6kpDQWmBDOiKeuBio3rbUGStkZXSuzkwTL7_SkT0_-pOfZi72xz2oo_sjfuDwwG4A3XcHuf5N8WN0Nyi-1KXpS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2275011431</pqid></control><display><type>article</type><title>Fulminant hepatitis as an immune‐related adverse event after nivolumab treatment</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Inamori, Osamu ; Miyagawa‐Hayashino, Aya ; Ueno, Akihisa ; Hongo, Fumiya ; Sonobe, Yuta ; Hojo, Tomohito ; Konishi, Eiichi</creator><creatorcontrib>Inamori, Osamu ; Miyagawa‐Hayashino, Aya ; Ueno, Akihisa ; Hongo, Fumiya ; Sonobe, Yuta ; Hojo, Tomohito ; Konishi, Eiichi</creatorcontrib><identifier>ISSN: 1320-5463</identifier><identifier>EISSN: 1440-1827</identifier><identifier>DOI: 10.1111/pin.12812</identifier><identifier>PMID: 31286591</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Aged, 80 and over ; Diabetes Mellitus, Type 1 - drug therapy ; Female ; fulminant hepatitis ; Hepatitis ; Humans ; immune‐related adverse event ; Massive Hepatic Necrosis - chemically induced ; Massive Hepatic Necrosis - pathology ; Monoclonal antibodies ; nivolumab ; Nivolumab - adverse effects ; treatment ; Treatment Outcome</subject><ispartof>Pathology international, 2019-07, Vol.69 (7), p.434-436</ispartof><rights>2019 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3442-1960068b8e258b892b1424d5675c0a3cc1a78ffcb34a5294a8efe5dec33d5db33</citedby><cites>FETCH-LOGICAL-c3442-1960068b8e258b892b1424d5675c0a3cc1a78ffcb34a5294a8efe5dec33d5db33</cites><orcidid>0000-0003-2366-7863 ; 0000-0001-5072-2640</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fpin.12812$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fpin.12812$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31286591$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Inamori, Osamu</creatorcontrib><creatorcontrib>Miyagawa‐Hayashino, Aya</creatorcontrib><creatorcontrib>Ueno, Akihisa</creatorcontrib><creatorcontrib>Hongo, Fumiya</creatorcontrib><creatorcontrib>Sonobe, Yuta</creatorcontrib><creatorcontrib>Hojo, Tomohito</creatorcontrib><creatorcontrib>Konishi, Eiichi</creatorcontrib><title>Fulminant hepatitis as an immune‐related adverse event after nivolumab treatment</title><title>Pathology international</title><addtitle>Pathol Int</addtitle><subject>Aged, 80 and over</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Female</subject><subject>fulminant hepatitis</subject><subject>Hepatitis</subject><subject>Humans</subject><subject>immune‐related adverse event</subject><subject>Massive Hepatic Necrosis - chemically induced</subject><subject>Massive Hepatic Necrosis - pathology</subject><subject>Monoclonal antibodies</subject><subject>nivolumab</subject><subject>Nivolumab - adverse effects</subject><subject>treatment</subject><subject>Treatment Outcome</subject><issn>1320-5463</issn><issn>1440-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtKAzEUhoMotlYXvoAMuHIxba5zWUpptVBURNchM3MGU-Zmkql05yP4jD6J0anuDIecA-fjO_AjdE7wlPg363QzJTQh9ACNCec4JAmND_3MKA4Fj9gInVi7wZjELMLHaMQ8HYmUjNHjsq9q3ajGBS_QKaedtoHy1QS6rvsGPt8_DFTKQRGoYgvGQgBb8LgqHZig0du26muVBc6AcrXfnKKjUlUWzvZ9gp6Xi6f5bbi-v1nNr9dhzjinIUkjjKMkS4AK_6c0I5zyQkSxyLFieU5UnJRlnjGuBE25SqAEUUDOWCGKjLEJuhy8nWlfe7BObtreNP6kpDQWmBDOiKeuBio3rbUGStkZXSuzkwTL7_SkT0_-pOfZi72xz2oo_sjfuDwwG4A3XcHuf5N8WN0Nyi-1KXpS</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Inamori, Osamu</creator><creator>Miyagawa‐Hayashino, Aya</creator><creator>Ueno, Akihisa</creator><creator>Hongo, Fumiya</creator><creator>Sonobe, Yuta</creator><creator>Hojo, Tomohito</creator><creator>Konishi, Eiichi</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><orcidid>https://orcid.org/0000-0003-2366-7863</orcidid><orcidid>https://orcid.org/0000-0001-5072-2640</orcidid></search><sort><creationdate>201907</creationdate><title>Fulminant hepatitis as an immune‐related adverse event after nivolumab treatment</title><author>Inamori, Osamu ; Miyagawa‐Hayashino, Aya ; Ueno, Akihisa ; Hongo, Fumiya ; Sonobe, Yuta ; Hojo, Tomohito ; Konishi, Eiichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3442-1960068b8e258b892b1424d5675c0a3cc1a78ffcb34a5294a8efe5dec33d5db33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged, 80 and over</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Female</topic><topic>fulminant hepatitis</topic><topic>Hepatitis</topic><topic>Humans</topic><topic>immune‐related adverse event</topic><topic>Massive Hepatic Necrosis - chemically induced</topic><topic>Massive Hepatic Necrosis - pathology</topic><topic>Monoclonal antibodies</topic><topic>nivolumab</topic><topic>Nivolumab - adverse effects</topic><topic>treatment</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Inamori, Osamu</creatorcontrib><creatorcontrib>Miyagawa‐Hayashino, Aya</creatorcontrib><creatorcontrib>Ueno, Akihisa</creatorcontrib><creatorcontrib>Hongo, Fumiya</creatorcontrib><creatorcontrib>Sonobe, Yuta</creatorcontrib><creatorcontrib>Hojo, Tomohito</creatorcontrib><creatorcontrib>Konishi, Eiichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Pathology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Inamori, Osamu</au><au>Miyagawa‐Hayashino, Aya</au><au>Ueno, Akihisa</au><au>Hongo, Fumiya</au><au>Sonobe, Yuta</au><au>Hojo, Tomohito</au><au>Konishi, Eiichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fulminant hepatitis as an immune‐related adverse event after nivolumab treatment</atitle><jtitle>Pathology international</jtitle><addtitle>Pathol Int</addtitle><date>2019-07</date><risdate>2019</risdate><volume>69</volume><issue>7</issue><spage>434</spage><epage>436</epage><pages>434-436</pages><issn>1320-5463</issn><eissn>1440-1827</eissn><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31286591</pmid><doi>10.1111/pin.12812</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0003-2366-7863</orcidid><orcidid>https://orcid.org/0000-0001-5072-2640</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1320-5463 |
| ispartof | Pathology international, 2019-07, Vol.69 (7), p.434-436 |
| issn | 1320-5463 1440-1827 |
| language | eng |
| recordid | cdi_proquest_journals_2275011431 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged, 80 and over Diabetes Mellitus, Type 1 - drug therapy Female fulminant hepatitis Hepatitis Humans immune‐related adverse event Massive Hepatic Necrosis - chemically induced Massive Hepatic Necrosis - pathology Monoclonal antibodies nivolumab Nivolumab - adverse effects treatment Treatment Outcome |
| title | Fulminant hepatitis as an immune‐related adverse event after nivolumab treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T05%3A23%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fulminant%20hepatitis%20as%20an%20immune%E2%80%90related%20adverse%20event%20after%20nivolumab%20treatment&rft.jtitle=Pathology%20international&rft.au=Inamori,%20Osamu&rft.date=2019-07&rft.volume=69&rft.issue=7&rft.spage=434&rft.epage=436&rft.pages=434-436&rft.issn=1320-5463&rft.eissn=1440-1827&rft_id=info:doi/10.1111/pin.12812&rft_dat=%3Cproquest_cross%3E2275011431%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2275011431&rft_id=info:pmid/31286591&rfr_iscdi=true |